<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01882478</url>
  </required_header>
  <id_info>
    <org_study_id>12-006030</org_study_id>
    <nct_id>NCT01882478</nct_id>
  </id_info>
  <brief_title>Cryotherapy -BEATS-RF Ablation Trial</brief_title>
  <official_title>CryoSpray Ablation for Barrett's Esophagus After Treatment Failure With Serial RadioFrequency Ablation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether cryotherapy is effective in the treatment&#xD;
      of persistent high grade dysplasia (HGD) or early esophageal adenocarcinoma (IMCA) in&#xD;
      patients who have not responded to radiofrequency ablation (RFA).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">June 2021</completion_date>
  <primary_completion_date type="Actual">June 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Response</measure>
    <time_frame>2 years</time_frame>
    <description>To assess efficacy of achieving elimination of dysplasia in patients with RFA-refractory BE with HGD or IMCA</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Predictors of response</measure>
    <time_frame>2 years</time_frame>
    <description>To identify potential predictors of CE-D and CE-IM in patients requiring rescue CSA treatment after failed RFA therapy</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">15</enrollment>
  <condition>Barrett's Esophagus With Persistent Dysplasia or</condition>
  <condition>Early Esophageal Adenocarcinoma Post Radio Frequency Ablation</condition>
  <arm_group>
    <arm_group_label>failure to respond to RF ablation</arm_group_label>
    <description>patients undergoing endoscopic RF ablation therapy with persistent BE with HGD or IMCA despite 2 or more serial RF ablation treatment sessions</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        patients with persistent BE with HGD or IMCA despite 2 or more serial RF ablation treatment&#xD;
        sessions in a cohort of patients undergoing endoscopic therapy.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 18 years old&#xD;
&#xD;
          -  Able to provide informed consent&#xD;
&#xD;
          -  Patients with unifocal or multifocal BE with HGD or IMCA who have failed at least 2&#xD;
             serial RFA therapy.&#xD;
&#xD;
          -  Patients who refused esophagectomy or deemed inoperable or whose BE dysplasia is not&#xD;
             amenable to endoscopic mucosal resection (EMR) treatment alone due to: (1) extensive&#xD;
             multifocal lesions (2) severe coagulopathy or any medical condition deemed high risk&#xD;
             for EMR (3) patient refuses EMR&#xD;
&#xD;
          -  Patients with a nodular BE lesions may undergo clinically-indicated EMR and still be&#xD;
             eligible for enrollment as long as they have BE-HGD lesion/s that are still candidate&#xD;
             for ablative treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age younger than 18 years old&#xD;
&#xD;
          -  Life expectancy less than 12 months&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Presence of esophageal varices&#xD;
&#xD;
          -  Esophageal stricture precluding passage of an endoscope and suction tubing&#xD;
&#xD;
          -  Any procedure that has impeded normal gastric emptying or limited gastric volume&#xD;
             distention, including but not limited to gastric bypass, stomach stapling,&#xD;
             gastrojejunostomy or any disease state has significantly reduced the elasticity in the&#xD;
             GI tract (e.g. Marfan's syndrome, Scleroderma or any Connective Tissue Disease)&#xD;
&#xD;
          -  Esophageal cancer (T2 and above)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kenneth K Wang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>June 18, 2013</study_first_submitted>
  <study_first_submitted_qc>June 18, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 20, 2013</study_first_posted>
  <last_update_submitted>October 18, 2021</last_update_submitted>
  <last_update_submitted_qc>October 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Kenneth K. Wang</investigator_full_name>
    <investigator_title>Kathy and Russ VanCleve Professor of Gastroenterology Reserach</investigator_title>
  </responsible_party>
  <keyword>Barrett's esophagus</keyword>
  <keyword>Early esophageal adenocarcinoma</keyword>
  <keyword>Radio Frequency Ablation</keyword>
  <keyword>Cryotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Barrett Esophagus</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

